Confounders and intermediaries in case-control study designs: A strategy for distinguishing between the two when measured using the same variable

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 3, 2011, Pages 221-228

  Gruneir, Andrea ^a,b,c   Marras, Connie ^d   Fischer, Hadas ^c   Wang, Xuesong ^c   Gill, Sudeep ^e   Rochon, Paula A ^a,b,c   Anderson, Geoffrey M ^a,b,c  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c INSTITUTE FOR CLINICAL EVALUATIVE SCIENCES   (Canada)

^d TORONTO WESTERN HOSPITAL   (Canada)

^e QUEEN S UNIVERSITY   (Canada)

Author keywords

Administrative data; Confounding by indication; Exposure classification; Nested case control design

Indexed keywords

ANTIPARKINSON AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

AGED; AGITATION; ARTICLE; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DELIRIUM; EXPOSURE VARIABLE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; OUTCOME VARIABLE; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOSIS; RISK FACTOR; STUDY DESIGN;

AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; CONFOUNDING FACTORS (EPIDEMIOLOGY); FEMALE; HUMANS; MALE; MODELS, STATISTICAL; MORTALITY; OBSERVER VARIATION; RESEARCH DESIGN; TREATMENT OUTCOME;

EID: 79951978833     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2058     Document Type: Article

References (10)

1. Csizmadi I, Collet JP, Boivin JF. Bias and confouding in pharmacoepidemiology. In: Pharmacoepidemiology (4th edn), Strom BE (ed.). pages 791-809. John Wiley & Sons Ltd: West Sussex, 2005.
2. Essebag V, Platt RW, Abrahamowicz M, Pilote L. Comparison of nested case-control and survival analysis methodologies for analysis of time-dependent exposure. BMC Med Res Methodol 2005; 5(5).
3. Marras C, Gruneir A, Wang X, et al. Antipsychotics and mortality in parkinsonism (under review).
4. Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146(11): 775-786.
5. Rochon PA, Normand SL, Gomes T, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Intern Med 2008; 168(10): 1090-1096.
6. Setoguchi S, Wang PS, Alan Brookhart, M, Canning CF, Kaci L, Schneeweiss S. Potential causes of higher mortality in elderly users of conventional and atypical antipsychotic medications. J Am Geriatr Soc 2008; 56(9): 1644-1650.
7. Simoni-Wastila L, Ryder PT, Qian J, Zuckerman IH, Shaffer T, Zhao L. Association of antipsychotic use with hospital events and mortality among Medicare beneficiaries residing in long-term care facilities. Am J Geriatr Psychiatry 2009; 17: 417-427.
8. Schneeweiss S, Setoguchi S, Brookhart A, Dormuth C, Wang PS. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007; 176(5): 627-632.
9. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294(15): 1934-1943.
10. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14(3): 191-210.